P Reed Maurer, long-time Japanese pharma industry watcher and president of International Alliances Limited (IAL), has written a series of exclusive articles for The Pharma Letter on growth strategies in Japan’s pharmaceutical market.
The first of these – on mergers and acquisitions, appears today, with the other four, covering: Co-promotion and Co-marketing; People, Products and Research and Development, to be published during the remainder of this week.
Mergers and acquisitions
Growth in any pharma market is often accelerated through timely mergers and acquisitions that give surviving entities critical mass. That is, a competitive advantage in drug development and commercialization. In Japan the only investment barrier for Western pharma companies since 1975 is their inability to make attractive acquisitions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze